711 related articles for article (PubMed ID: 25466242)
1. Anti-albuminuric effect of the aldosterone blocker eplerenone in non-diabetic hypertensive patients with albuminuria: a double-blind, randomised, placebo-controlled trial.
Ando K; Ohtsu H; Uchida S; Kaname S; Arakawa Y; Fujita T;
Lancet Diabetes Endocrinol; 2014 Dec; 2(12):944-53. PubMed ID: 25466242
[TBL] [Abstract][Full Text] [Related]
2. Rationale and design of the Eplerenone combination Versus conventional Agents to Lower blood pressure on Urinary Antialbuminuric Treatment Effect (EVALUATE) trial: a double-blinded randomized placebo-controlled trial to evaluate the antialbuminuric effects of an aldosterone blocker in hypertensive patients with albuminuria.
Ando K; Ohtsu H; Arakawa Y; Kubota K; Yamaguchi T; Nagase M; Yamada A; Fujita T;
Hypertens Res; 2010 Jun; 33(6):616-21. PubMed ID: 20379190
[TBL] [Abstract][Full Text] [Related]
3. Selective aldosterone blockade with eplerenone reduces albuminuria in patients with type 2 diabetes.
Epstein M; Williams GH; Weinberger M; Lewin A; Krause S; Mukherjee R; Patni R; Beckerman B
Clin J Am Soc Nephrol; 2006 Sep; 1(5):940-51. PubMed ID: 17699311
[TBL] [Abstract][Full Text] [Related]
4. Aldosterone synthase inhibitor (BI 690517) therapy for people with diabetes and albuminuric chronic kidney disease: A multicentre, randomized, double-blind, placebo-controlled, Phase I trial.
Bornstein SR; de Zeeuw D; Heerspink HJL; Schulze F; Cronin L; Wenz A; Tuttle KR; Hadjadj S; Rossing P
Diabetes Obes Metab; 2024 Jun; 26(6):2128-2138. PubMed ID: 38497241
[TBL] [Abstract][Full Text] [Related]
5. Effect of Finerenone on Albuminuria in Patients With Diabetic Nephropathy: A Randomized Clinical Trial.
Bakris GL; Agarwal R; Chan JC; Cooper ME; Gansevoort RT; Haller H; Remuzzi G; Rossing P; Schmieder RE; Nowack C; Kolkhof P; Joseph A; Pieper A; Kimmeskamp-Kirschbaum N; Ruilope LM;
JAMA; 2015 Sep; 314(9):884-94. PubMed ID: 26325557
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and safety of aldosterone synthase inhibition with and without empagliflozin for chronic kidney disease: a randomised, controlled, phase 2 trial.
Tuttle KR; Hauske SJ; Canziani ME; Caramori ML; Cherney D; Cronin L; Heerspink HJL; Hugo C; Nangaku M; Rotter RC; Silva A; Shah SV; Sun Z; Urbach D; de Zeeuw D; Rossing P;
Lancet; 2024 Jan; 403(10424):379-390. PubMed ID: 38109916
[TBL] [Abstract][Full Text] [Related]
7. Efficacy of a novel inhibitor of vascular adhesion protein-1 in reducing albuminuria in patients with diabetic kidney disease (ALBUM): a randomised, placebo-controlled, phase 2 trial.
de Zeeuw D; Renfurm RW; Bakris G; Rossing P; Perkovic V; Hou FF; Nangaku M; Sharma K; Heerspink HJL; Garcia-Hernandez A; Larsson TE
Lancet Diabetes Endocrinol; 2018 Dec; 6(12):925-933. PubMed ID: 30413396
[TBL] [Abstract][Full Text] [Related]
8. Albuminuria-lowering effect of dapagliflozin alone and in combination with saxagliptin and effect of dapagliflozin and saxagliptin on glycaemic control in patients with type 2 diabetes and chronic kidney disease (DELIGHT): a randomised, double-blind, placebo-controlled trial.
Pollock C; Stefánsson B; Reyner D; Rossing P; Sjöström CD; Wheeler DC; Langkilde AM; Heerspink HJL
Lancet Diabetes Endocrinol; 2019 Jun; 7(6):429-441. PubMed ID: 30992195
[TBL] [Abstract][Full Text] [Related]
9. Can patiromer allow for intensified renin-angiotensin-aldosterone system blockade with losartan and spironolactone leading to decreased albuminuria in patients with chronic kidney disease, albuminuria and hyperkalaemia? An open-label randomised controlled trial: MorphCKD.
Mårup FH; Peters CD; Christensen JH; Birn H
BMJ Open; 2022 Feb; 12(2):e057503. PubMed ID: 35190442
[TBL] [Abstract][Full Text] [Related]
10. Effects of empagliflozin on the urinary albumin-to-creatinine ratio in patients with type 2 diabetes and established cardiovascular disease: an exploratory analysis from the EMPA-REG OUTCOME randomised, placebo-controlled trial.
Cherney DZI; Zinman B; Inzucchi SE; Koitka-Weber A; Mattheus M; von Eynatten M; Wanner C
Lancet Diabetes Endocrinol; 2017 Aug; 5(8):610-621. PubMed ID: 28666775
[TBL] [Abstract][Full Text] [Related]
11. Albuminuria-Lowering Effect of Dapagliflozin, Eplerenone, and Their Combination in Patients with Chronic Kidney Disease: A Randomized Crossover Clinical Trial.
Provenzano M; Puchades MJ; Garofalo C; Jongs N; D'Marco L; Andreucci M; De Nicola L; Gorriz JL; Heerspink HJL; ;
J Am Soc Nephrol; 2022 Aug; 33(8):1569-1580. PubMed ID: 35440501
[TBL] [Abstract][Full Text] [Related]
12. Early detection of diabetic kidney disease by urinary proteomics and subsequent intervention with spironolactone to delay progression (PRIORITY): a prospective observational study and embedded randomised placebo-controlled trial.
Tofte N; Lindhardt M; Adamova K; Bakker SJL; Beige J; Beulens JWJ; Birkenfeld AL; Currie G; Delles C; Dimos I; Francová L; Frimodt-Møller M; Girman P; Göke R; Havrdova T; Heerspink HJL; Kooy A; Laverman GD; Mischak H; Navis G; Nijpels G; Noutsou M; Ortiz A; Parvanova A; Persson F; Petrie JR; Ruggenenti PL; Rutters F; Rychlík I; Siwy J; Spasovski G; Speeckaert M; Trillini M; Zürbig P; von der Leyen H; Rossing P;
Lancet Diabetes Endocrinol; 2020 Apr; 8(4):301-312. PubMed ID: 32135136
[TBL] [Abstract][Full Text] [Related]
13. Effects of eplerenone, enalapril, and eplerenone/enalapril in patients with essential hypertension and left ventricular hypertrophy: the 4E-left ventricular hypertrophy study.
Pitt B; Reichek N; Willenbrock R; Zannad F; Phillips RA; Roniker B; Kleiman J; Krause S; Burns D; Williams GH
Circulation; 2003 Oct; 108(15):1831-8. PubMed ID: 14517164
[TBL] [Abstract][Full Text] [Related]
14. Clinical effects of eplerenone, a selective aldosterone blocker, in Japanese patients with essential hypertension.
Sato A; Fukuda S
J Hum Hypertens; 2010 Jun; 24(6):387-94. PubMed ID: 19865106
[TBL] [Abstract][Full Text] [Related]
15. The effect of CCR2 inhibitor CCX140-B on residual albuminuria in patients with type 2 diabetes and nephropathy: a randomised trial.
de Zeeuw D; Bekker P; Henkel E; Hasslacher C; Gouni-Berthold I; Mehling H; Potarca A; Tesar V; Heerspink HJ; Schall TJ;
Lancet Diabetes Endocrinol; 2015 Sep; 3(9):687-96. PubMed ID: 26268910
[TBL] [Abstract][Full Text] [Related]
16. Safety and efficacy of eplerenone in patients at high risk for hyperkalemia and/or worsening renal function: analyses of the EMPHASIS-HF study subgroups (Eplerenone in Mild Patients Hospitalization And SurvIval Study in Heart Failure).
Eschalier R; McMurray JJ; Swedberg K; van Veldhuisen DJ; Krum H; Pocock SJ; Shi H; Vincent J; Rossignol P; Zannad F; Pitt B;
J Am Coll Cardiol; 2013 Oct; 62(17):1585-93. PubMed ID: 23810881
[TBL] [Abstract][Full Text] [Related]
17. Effects of eplerenone versus losartan in patients with low-renin hypertension.
Weinberger MH; White WB; Ruilope LM; MacDonald TM; Davidson RC; Roniker B; Patrick JL; Krause SL
Am Heart J; 2005 Sep; 150(3):426-33. PubMed ID: 16169319
[TBL] [Abstract][Full Text] [Related]
18. The enhanced renin-angiotensin-aldosteron system pharmacological blockade--which is the best?
Tylicki L; Lizakowski S; Rutkowski P; Renke M; Sulikowska B; Heleniak Z; Donderski R; Bednarski R; Przybylska M; Manitius J; Rutkowski B
Kidney Blood Press Res; 2012; 36(1):335-43. PubMed ID: 23235363
[TBL] [Abstract][Full Text] [Related]
19. Mineralocorticoid receptor blockade suppresses dietary salt-induced ACEI/ARB-resistant albuminuria in non-diabetic hypertension: a sub-analysis of evaluate study.
Nishimoto M; Ohtsu H; Marumo T; Kawarazaki W; Ayuzawa N; Ueda K; Hirohama D; Kawakami-Mori F; Shibata S; Nagase M; Isshiki M; Oba S; Shimosawa T; Fujita T
Hypertens Res; 2019 Apr; 42(4):514-521. PubMed ID: 30631161
[TBL] [Abstract][Full Text] [Related]
20. Assessment of the novel selective aldosterone blocker eplerenone using ambulatory and clinical blood pressure in patients with systemic hypertension.
White WB; Carr AA; Krause S; Jordan R; Roniker B; Oigman W
Am J Cardiol; 2003 Jul; 92(1):38-42. PubMed ID: 12842242
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
